Last $39.90 USD
Change Today +0.21 / 0.53%
Volume 468.9K
As of 8:10 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

kythera biopharmaceuticals i (KYTH) Snapshot

Open
$39.64
Previous Close
$39.69
Day High
$40.48
Day Low
$38.60
52 Week High
03/11/14 - $50.00
52 Week Low
05/9/14 - $29.50
Market Cap
907.9M
Average Volume 10 Days
367.8K
EPS TTM
$-4.53
Shares Outstanding
22.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KYTHERA BIOPHARMACEUTICALS I (KYTH)

kythera biopharmaceuticals i (KYTH) Related Bloomberg News

View More Bloomberg News

kythera biopharmaceuticals i (KYTH) Related Businessweek News

No Related Businessweek News Found

kythera biopharmaceuticals i (KYTH) Details

KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market. It is developing ATX-101, is an injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. The company also has various additional research programs around therapeutic intervention for hair loss; and maintains active research interest in hair and fat biology, pigmentation modulation, and facial contouring. KYTHERA Biopharmaceuticals, Inc. has a collaboration arrangement with Bayer Consumer Care AG and a related collaboration agreement with Bayer Consumer Care AG’s affiliate, Intendis GmbH to develop and commercialize ATX-101 outside the United States and Canada. The company was formerly known as AESTHERx, Inc. and changed its name to KYTHERA Biopharmaceuticals, Inc. in July 2006. KYTHERA Biopharmaceuticals, Inc. was founded in 2004 and is headquartered in Calabasas, California.

kythera biopharmaceuticals i (KYTH) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $448.7K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $312.7K
Chief Medical Officer
Total Annual Compensation: $348.8K
Compensation as of Fiscal Year 2013.

kythera biopharmaceuticals i (KYTH) Key Developments

Kythera Biopharmaceuticals, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Kythera Biopharmaceuticals, Inc. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net loss of $24,223,000 or $1.07 per basic and diluted share against $14,018,000 or $0.66 per basic and diluted share a year ago. Loss from operations was $23,157,000 compared to $13,563,000 a year ago. For the full year, the company reported net loss of $135,621,000 or $6.04 per basic and diluted share against $51,911,000 or $2.71 per basic and diluted share a year ago. Loss from operations was $131,652,000 compared to $50,066,000 a year ago.

Kythera Biopharmaceuticals, Inc. Enters into License Agreements with Actelion Pharmaceuticals

Kythera Biopharmaceuticals, Inc. entered into a license agreements with Actelion Pharmaceuticals Ltd. for a novel approach for the treatment of hair loss. Kythera Biopharmaceuticals and Actelion Pharmaceuticals are biopharmaceutical companies based in the US and Switzerland, respectively. Under the terms of the agreement, KYTHERA Holdings Ltd. licensed the worldwide rights to setipiprant, a clinical-stage selective and potent oral antagonist to the prostaglandin D2 (PGD2) receptor. As part of the agreement, Actelion will be eligible to receive up to $27 million in potential development and regulatory milestones, as well as royalties on sales if setipiprant is successfully commercialized.

Kythera Biopharmaceuticals, Inc. Submits Drug Application in Australia for Submental Contouring Injectable Drug ATX-101

KYTHERA Biopharmaceuticals, Inc. announced its submission to Australia's Therapeutic Goods Administration (TGA) for ATX-101 (deoxycholic acid), its potential first-in-class treatment for improving submental fullness associated with submental (under the chin) fat. The application in Australia is supported by results from two pivotal Phase III trials: REFINE-1 and REFINE-2. Data from the trials, first reported in 2013, demonstrated that the majority of ATX-101 patients had a visible reduction in fat under the chin and reported significant improvement in the visual and emotional impact of treatment. The global facial aesthetics market is estimated to reach $4.7 billion annually by 2018.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KYTH:US $39.90 USD +0.21

KYTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KYTH.
View Industry Companies
 

Industry Analysis

KYTH

Industry Average

Valuation KYTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 11.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYTHERA BIOPHARMACEUTICALS I, please visit www.kytherabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.